RxDoctor Payments Data

Tina Withrow

Family · North Charleston, SCNPI 1063928521

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,914 of the $19,182 with a category attached, or 83.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,182in general payments, 2019–2025

Across 679 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Novartis$1K
  • AstraZeneca$1K
  • Merck$949
  • Bristol Myers Squibb$835
  • E.r. Squibb & Sons, L.L.C.$799
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$2,37512%
  • Travel & lodging$580%
  • Food & beverage$15,91483%
  • Education$4532%
  • Other$3822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen28$2,979
Novartis53$1,437
AstraZeneca(2 entities)57$1,337
Merck39$949
Bristol Myers Squibb43$835
E.r. Squibb & Sons, L.L.C.42$799
Lilly USA, LLC27$705
Johnson & Johnson27$670
Genentech USA, Inc.27$614
Sanofi16$595
Daiichi Sankyo Inc.16$575
Takeda Pharmaceuticals U.S.A., Inc.20$540
AbbVie17$521
Incyte Corporation16$488
Gilead(2 entities)20$464
Pfizer24$443
Novocure Inc.4$372
GSK18$369
Jazz Pharmaceuticals Inc.14$291
Taiho Oncology, Inc.14$287
Regeneron Healthcare Solutions, Inc.11$261
Seagen Inc.10$234
Rigel Pharmaceuticals, Inc.5$225
Sanofi-aventis U.S. LLC2$200
Adaptive Biotechnologies Corporation8$182
Eisai Inc.8$165
AVEO Pharmaceuticals, Inc.6$161
Bayer6$146
Epizyme, Inc.2$140
Pharmacyclics LLC, An Abbvie Company7$134
Sobi, Inc5$132
Beigene USA, Inc.5$119
Boehringer Ingelheim5$114
Deciphera Pharmaceuticals Inc.5$113
TG Therapeutics, Inc.1$107
Stemline Therapeutics Inc.4$103
Puma Biotechnology, Inc.5$97
Karyopharm Therapeutics Inc.4$97
Servier Pharmaceuticals LLC4$92
ADC Therapeutics America, Inc.5$92
G1 Therapeutics, Inc.4$84
Beone Medicines USA, Inc.4$73
Acrotech Biopharma Inc.3$68
Array Biopharma Inc3$60
Iovance Biotherapeutics, Inc.2$56
Recordati_rare_diseases_inc.2$55
CTI Biopharma Corp.3$55
EMD Serono, Inc.3$54
Morphosys, US Inc.3$50
Geron Corporation2$49
Genmab U.S., Inc.2$48
Astellas Pharma US Inc3$47
Myovant Sciences Inc.2$39
Accord Healthcare, Inc.1$33
Tersera Therapeutics LLC2$32
Fennec Pharmaceuticals, Inc.1$24
Pharmaessentia USA Corporation1$24
Blue Earth Diagnostics1$20
Syndax Pharmaceuticals, Inc.1$19
Mirati Therapeutics, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,182 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$79,079
Medicare patients
370
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib14$217,489
EliquisApixaban32$24,124
Anastrozole50$1,624
Tamoxifen Citrate34$1,403
Ondansetron OdtOndansetron58$949
Prochlorperazine Maleate40$591
Letrozole33$558
Potassium Chloride11$452
Morphine Sulfate ErMorphine Sulfate13$389
Dexamethasone22$388
Lidocaine-PrilocaineLidocaine/Prilocaine19$225
Acyclovir12$91
Levofloxacin22$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$443$241,61246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →